Preparation method for preparing a therapeutical composition for internal use, particularly to be administered by mouth, in galenical presentation, and containing at least one active principle in solid form adsorbed on a substrate, the active product being distributed therein as finely dispersed microparticles. The method includes dissolving the starting active principle in an appropriate solvent, impregnating the solution thus formed on a food support having an appropriate structure and pharmac...

A method of enhancing the anticoagulant effect of aspirin is disclosed, wherein salicylamide is coadministered. Salicylamide is essentially without anticoagulant effects of its own. A normal dose of salicylamide, approximately 30 mg to about 3.0 grams administered daily, or about 3 to 9 mg/kg body weight, can increase the anticoagulant effect of aspirin. This is particularly desirable in patients who are undergoing long-term anticoagulant therapy, e.g., cardiac patients.

There is disclosed a pharmaceutical composition for inhibiting the platelet aggregation comprising acetylsalicyclic acid or a pharmaceutically acceptable salt thereof and a 1,5-benzothiazepine derivative of the formula: ##STR1## wherein R.sup.1 is a lower alkyl group or a lower alkoxy group, R.sup.2 is hydrogen atom or a lower alkanoyl group, R.sup.3 is a lower alkyl group, R.sup.4 is hydrogen atom or a lower alkyl group and R.sup.5 is a lower alkyl group or a halogen atom, or a pharmaceutically...

Disclosed are unique methods for identifying the lowest, yet optimal, aspirin doses for patients. These methods are also characterized as having little to no aspirin-related side-effects. These methods may be used pre- as well as post-thrombotic event, and employs a patient's urinary thromboxane B.sub.2 metabolic levels (e.g., 11-dehydrothromboxane B.sub.2), to identify the patient's platelet activation level. A patient's urinary thromboxane B.sub.2 metabolic level is then used to calculate and ...

The method of providing cytoprotection of the gastric mucosa in a mammal receiving aspirin perorally which comprises orally administering either prior to or in combination with aspirin a cytoprotectively effective amount of sodium thiosulfate alone or in combination with a pharmaceutically acceptable carrier. Also shown is a composition for providing cytoprotection of the gastric mucosa in a mammal receiving aspirin perorally which comprises aspirin in combination with a cytoprotectively effecti...

Mecidinal specialty in galenic presentation and constituted in particular by a pastille, granule, pill, tablet or the like, adapted to be sucked by the user or with sublingual administration. At least one active product in microdispersed form within the substrate. Method of presenting a therapeutical composition for internal use, particularly for administration per os, in galenic presentation, and containing at least one active principle in solid form adsorbed on a substrate. The active product ...

A method of manufacturing a stabilized, essentially sodium free, granular aspirin compound mixed with a granular potassium bicarbonate compound comprising the steps of determining a desirable dose size of such aspirin compound which is to be packaged. Weighing out an amount of granular aspirin based on the dose size determined. Placing an amount of such granular potassium bicarbonate compound into a container which is uniformly distributed over a bottom surface of such container to a predetermin...

A method and controlled release oral unit dosage form of acetylsalicylic acid (aspirin) delays the release of the drug until a predetermined time interval after ingestion. This enables the drug to reach optimal therapeutic blood levels at a time in the early morning when the events leading up to a vascular obstruction culminating in a heart attack or stroke are most commonly occurring after the drug is taken in the evening. The convenience of taking the drug every evening should enhance complian...

A method is disclosed for inducing thromboxane suppression in a mammalian subject by percutaneously administering a pharmaceutical composition containing aspirin. Articles useful for practicing the therapeutic methods of the invention are also disclosed.

A coated aspirin tablet, which is capable of being disintegrated quickly in gastric fluid, containing a thin film of plasticized ethylcellulose. The ethylcellulose thin film coating represents less than about 2 wt % of the coated tablet weight and is the dried residue of an aqueous ethylcellulose dispersion that is spray-coated onto the tablet.